© 2021 Smart + Strong. All Rights Reserved. Terms of use and Your privacy. Smart + Strong® is a registered trademark of CDM Publishing, LLC.
The Food and Drug Administration has approved AbbVie’s once-daily Mavyret to treat all six major genotypes of hepatitis C virus (HCV).
It approved 12 weeks of Gilead Sciences’ Vosevi for the re-treatment of adults with all genotypes of HCV who do not have cirrhorsis.
The triple-drug regimen comes in a once-daily single tablet.
EDP-239, a new NS5A inhibitor hepatitis C treatment from Enanta, showed promise in a small single-dose monotherapy study.
Abbott has announced Phase III trials of three direct acting agents, ABT-450/r, ABT-267, ABT-333, which together have shown high cure rates in...
A combination of daclatasvir and sofosbuvir produced cures in more than 93 percent of hepatitis C patients, with or without the addition of ri...
Gilead Sciences? pair of investigatory hepatitis C virus therapies led to a 100 percent cure rate among a small cohort of patients.
Abbott Laboratories’ three-drug regimen cured 97 percent of treatment-naive hepatitis C patients and 93 percent of those who had failed a prev...
ACH-3102, a hepatitis C drug under development by Achillion Pharmaceuticals, has received Fast Track status from the FDA, according to an...
A 24-week, interferon-free regimen pairing two drugs from Bristol-Myers Squibb--60 milligrams (mg) of daclatasvir, a once-daily NS5a...
Combining two experimental oral hepatitis C drugs from Bristol-Myers Squibb (BMS)--daclatasvir, a once-daily NS5a inhibitor, and...
Adding BMS-790052, an experimental hepatitis C drug being developed by Bristol-Myers Squibb, to pegylated interferon and ribavirin...
Pharmasset Inc. has started its Phase II clinical trial investigating the combination of its nucleotide polymerase inhibitor PSI-7977 and...
A clinical trial suggests at least some cases of chronic HCV infection can be cured without use of either pegylated interferon or ribavirin.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.